RWA Wealth Partners LLC Sells 357 Shares of Agilent Technologies, Inc. (NYSE:A)

RWA Wealth Partners LLC trimmed its position in Agilent Technologies, Inc. (NYSE:A) by 18.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,527 shares of the medical research company’s stock after selling 357 shares during the quarter. RWA Wealth Partners LLC’s holdings in Agilent Technologies were worth $205,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Schroder Investment Management Group raised its position in shares of Agilent Technologies by 0.5% during the 4th quarter. Schroder Investment Management Group now owns 88,300 shares of the medical research company’s stock valued at $11,847,000 after acquiring an additional 405 shares during the last quarter. Allstate Corp bought a new stake in Agilent Technologies in the fourth quarter valued at about $1,144,000. Brown Brothers Harriman & Co. lifted its stake in Agilent Technologies by 59.9% in the fourth quarter. Brown Brothers Harriman & Co. now owns 1,033 shares of the medical research company’s stock valued at $139,000 after buying an additional 387 shares during the period. DnB Asset Management AS boosted its holdings in Agilent Technologies by 1.5% during the fourth quarter. DnB Asset Management AS now owns 51,014 shares of the medical research company’s stock worth $6,853,000 after buying an additional 741 shares during the last quarter. Finally, Orion Portfolio Solutions LLC grew its position in shares of Agilent Technologies by 8.2% during the 4th quarter. Orion Portfolio Solutions LLC now owns 9,209 shares of the medical research company’s stock worth $1,237,000 after buying an additional 696 shares during the period.

Agilent Technologies Trading Down 2.8 %

NYSE A opened at $113.67 on Wednesday. The stock has a market capitalization of $32.41 billion, a price-to-earnings ratio of 26.13, a PEG ratio of 3.27 and a beta of 1.11. Agilent Technologies, Inc. has a 52 week low of $113.36 and a 52 week high of $155.35. The stock’s 50 day moving average price is $132.90 and its two-hundred day moving average price is $136.32. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.66 and a current ratio of 2.20.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.27 by $0.04. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. The business had revenue of $1.68 billion during the quarter, compared to analysts’ expectations of $1.67 billion. As a group, analysts anticipate that Agilent Technologies, Inc. will post 5.57 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be given a $0.248 dividend. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date is Tuesday, April 1st. Agilent Technologies’s dividend payout ratio is currently 22.76%.

Insider Buying and Selling

In other news, VP Rodney Gonsalves sold 1,908 shares of Agilent Technologies stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $121.98, for a total value of $232,737.84. Following the completion of the transaction, the vice president now owns 21,786 shares of the company’s stock, valued at $2,657,456.28. This trade represents a 8.05 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Padraig Mcdonnell sold 1,911 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the transaction, the chief executive officer now owns 39,652 shares in the company, valued at $5,947,800. This represents a 4.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on A shares. StockNews.com raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday, December 24th. Barclays raised shares of Agilent Technologies from an “underweight” rating to an “equal weight” rating and boosted their price target for the company from $135.00 to $145.00 in a report on Monday, February 10th. Robert W. Baird dropped their price objective on Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating on the stock in a research note on Thursday, February 27th. Wells Fargo & Company decreased their target price on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating for the company in a research note on Monday, December 9th. Finally, Citigroup raised their price target on Agilent Technologies to $165.00 and gave the stock a “buy” rating in a research report on Thursday, December 19th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Agilent Technologies presently has a consensus rating of “Moderate Buy” and a consensus price target of $150.83.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.